FUJIFILM Announces Agreement to Acquire Kalon Biotherapeutics

Published on: 

FUJIFILM announced an agreement to acquire Kalon Biotherapeutics, a biopharmaceutical contract manufacturing organization specializing in vaccine manufacturing.


FUJIFILM Corp. will enter the vaccine CMO market with the acquisition of Kalon Biotherapeutics, a biologics development and manufacturing service provider out of Texas. FUJIFILM subsidiary, FUJIFILM Diosynth Biotechnologies (FDBU), will acquire 49% of the total membership interests in Kalon and will be entitled to appoint a majority of Kalon’s board members. Based on milestone achievements, FDBU may acquire 100% interest share.


The acquisition will strengthen FUJIFILM’s stance in the pharmaceutical industry. This announcement comes shortly after the announcement that FUJIFILM would start producing Avigan, an experimental treatment for Ebola.